Table 2.
Average end-plate currents measured in EDL nerve-muscle preparations in the control group, groups treated with BoNT/A alone, capsaicin + BoNT/A, and capsazepine + capsaicin + BoNT/A
| Pulse | Control (n = 3, 9) | + BoNT/A (n = 6, 12) | + CAP + BoNT/A (n = 6, 12) | + CPZ + CAP + BoNT/A (n = 4, 12) |
|---|---|---|---|---|
| 20-Hz EPC amplitude (nA) | ||||
| 1 | 170.69 ± 15.47 | 2.69 ± 8.23 | 100.23 ± 8.2 | 3.60 ± 2.52 |
| 10 | 156.86 ± 17.23 | 1.81 ± 3.45 | 113.45 ± 16.12 | 1.82 ± 3.52 |
| 20 | 157.51 ± 17.14 | 0.44 ± 2.28 | 105.52 ± 11.74 | 0.48 ± 2.14 |
| 30 | 163.41 ± 16.63 | 2.16 ± 3.06 | 109.45 ± 5.26 | 0.22 ± 3.14 |
| 40 | 160.61 ± 16.76 | 1.98 ± 3.26 | 107.21 ± 8.45 | 2.03 ± 3.19 |
| 50-Hz EPC amplitude (nA) | ||||
| 1 | 188.44 ± 17.34 | 0.53 ± 3.24 | 136.53 ± 13.22 | 1.22 ± 1.45 |
| 10 | 199.08 ± 10.39 | 2.06 ± 2.14 | 148.23 ± 18.91 | 2.28 ± 1.43 |
| 20 | 175.21 ± 9.31 | 2.08 ± 2.18 | 135.84 ± 25.6 | 1.99 ± 0.91 |
| 30 | 173.42 ± 9.06 | 6.19 ± 2.43 | 128.99 ± 25.82 | 3.41 ± 1.39 |
| 40 | 173.18 ± 8.77 | 0.89 ± 1.56 | 109.92 ± 43.14 | 2.45 ± 1.46 |
| 70-Hz EPC amplitude (nA) | ||||
| 1 | 229.37 ± 13.36 | 0.75 ± 1.33 | 149.34 ± 14.59 | 1.11 ± 2.41 |
| 10 | 248.28 ± 11.99 | 1.64 ± 0.85 | 237.08 ± 48.05 | 1.46 ± 1.52 |
| 20 | 243.03 ± 12.77 | 1.29 ± 1.78 | 130.29 ± 19.28 | 2.02 ± 1.31 |
| 30 | 247.28 ± 11.65 | 2.13 ± 1.18 | 121.19 ± 18.39 | 1.17 ± 1.24 |
| 40 | 246.31 ± 14.57 | 1.31 ± 0.54 | 122.63 ± 18.18 | 0.19 ± 1.46 |